Dealings in Securities by an Executive Director and Executive Officers of AngloGold Ashanti plc
Name of Executive Director
Gillian Doran
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
Off-market receipt of vested shares under the 2023 Deferred Share Plans (DSP)
Class of security
Ordinary shares
Number of securities
22,325
Price per security
Nil
Nature and extent of interest
Direct, Beneficial
Expand
Name of Executive Director
Gillian Doran
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
On-market sale of shares to fund tax liability in relation to DSP awards
Class of security
Ordinary shares
Number of securities sold
8,260
Price per security
US$40.3758 1
Value of transaction (excluding fees)
US$333,504.21
Nature and extent of interest
Direct, Beneficial
Expand
(1)
Weighted average price. These shares were sold in multiple transactions at prices ranging from US$40.3737 to US$40.3783 inclusive.
Expand
Name of Executive Officer
Terry Briggs
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
Off-market receipt of vested shares under the 2023 Deferred Share Plans (DSP)
Class of security
Ordinary shares
Number of securities
25,514
Price per security
Nil
Nature and extent of interest
Direct, Beneficial
Expand
Name of Executive Officer
Terry Briggs
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
On-market sale of vested DSP awards
Class of security
Ordinary shares
Number of securities sold
9,440
Price per security
US$40.3937 1
Value of transaction (excluding fees)
US$381,316.55
Nature and extent of interest
Direct, Beneficial
Expand
(1)
Weighted average price. These shares were sold in multiple transactions at prices ranging from US$40.3755 to US$40.4001 inclusive.
Expand
Name of Executive Officer
Marcelo Godoy
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
Off-market receipt of vested shares under the 2023 Deferred Share Plans (DSP)
Class of security
Ordinary shares
Number of securities
25,745
Price per security
Nil
Nature and extent of interest
Direct, Beneficial
Expand
Name of Executive Officer
Marcelo Godoy
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
On-market sale of vested DSP awards
Class of security
Ordinary shares
Number of securities sold
9,526
Price per security
US$40.3750 1
Value of transaction (excluding fees)
US$384,612.69
Nature and extent of interest
Direct, Beneficial
Expand
(1)
Weighted average price. These shares were sold in multiple transactions at prices ranging from US$40.3627 to US$40.4104 inclusive.
Expand
JSE Sponsor: The Standard Bank of South Africa Limited
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Bunge Global SA Just Beat EPS By 134%: Here's What Analysts Think Will Happen Next
Bunge Global SA (NYSE:BG) just released its latest quarterly results and things are looking bullish. It was overall a positive result, with revenues beating expectations by 2.8% to hit US$13b. Bunge Global also reported a statutory profit of US$2.61, which was an impressive 134% above what the analysts had forecast. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. After the latest results, the twin analysts covering Bunge Global are now predicting revenues of US$64.1b in 2025. If met, this would reflect a substantial 26% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 6.4% to US$7.33. Before this earnings report, the analysts had been forecasting revenues of US$52.7b and earnings per share (EPS) of US$7.70 in 2025. Although revenue sentiment looks to be improving, the analysts have made a small dip in per-share earnings estimates, perhaps acknowledging the investment required to grow the business. View our latest analysis for Bunge Global The consensus price target was unchanged at US$88.00, suggesting the business is performing roughly in line with expectations, despite some adjustments to profit and revenue forecasts. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Bunge Global's growth to accelerate, with the forecast 59% annualised growth to the end of 2025 ranking favourably alongside historical growth of 3.9% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 3.2% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Bunge Global is expected to grow much faster than its industry. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Bunge Global. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that in mind, we wouldn't be too quick to come to a conclusion on Bunge Global. Long-term earnings power is much more important than next year's profits. We have analyst estimates for Bunge Global going out as far as 2026, and you can see them free on our platform here. You still need to take note of risks, for example - Bunge Global has 4 warning signs (and 2 which can't be ignored) we think you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 minutes ago
- Yahoo
Ocugen Second Quarter 2025 Earnings: Beats Expectations
Ocugen (NASDAQ:OCGN) Second Quarter 2025 Results Key Financial Results Revenue: US$1.37m (up 20% from 2Q 2024). Net loss: US$14.7m (loss narrowed by 3.5% from 2Q 2024). US$0.05 loss per share (improved from US$0.059 loss in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Ocugen Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 12%. Looking ahead, revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 8.8% from a week ago. Risk Analysis It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Ocugen (at least 1 which is a bit concerning), and understanding them should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
35 minutes ago
- Yahoo
Grant Cardone's Most Hated Advice: Does It Make Sense For You?
Grant Cardone isn't afraid to say what he's really thinking — even if it stirs controversy. The wealthy entrepreneur and real estate investor is frequently interviewed and always seems to give his raw, unfiltered take on subjects like personal finance. For You: Try This: In an Instagram post, Cardone highlighted his two most hated pieces of advice. Keep reading to find out exactly what he said that's controversial and if it applies to your unique situation. 'Most People Should Not Go To College' In 2024, 19.3 million students were enrolled in undergraduate programs at U.S. colleges and universities, according to the Education Data Initiative. This represents an 8.4% decline from peak enrollment in 2010. Despite this, almost half of Americans have earned at least some type of college degree. As of 2022 — the most recent data available — 47% of Americans had an associate's degree or higher, according to the U.S. Census Bureau. Many surely disagree with him, but Cardone doesn't necessarily believe earning a degree is important. 'Most people should not go to college,' he said on an episode of the 'Success Story Podcast.' He said it's crazy that people spend years going to college — while spending money, instead of earning it — to acquire knowledge they could gain from an iPad. See Next: Worth noting that in 2021, approximately 68% of all jobs required at least some postsecondary education, according to the Georgetown University's Center on Education and the Workforce. By 2031, this number is expected to rise to 72%, with 42% of all jobs requiring a bachelor's degree. Clearly, the decision on whether or not to go to college largely depends on your career goals. You might be able to learn a lot from an iPad, but it won't get you hired by an employer that requires a formal degree. 'A House Is a Terrible Investment' Owning your home is long-been a cornerstone of the American dream. However, Cardone blatantly disagreed. On the 'Digital Social Hour Podcast,' he said owning your own home is a terrible investment, because it doesn't offer cash flow or big tax write-offs. 'You have no leverage,' he said. 'You're living in it, you're paying for it, you never own it.' Even if you do pay the mortgage off, he said you're still on the hook for costs like property taxes, insurance and maintenance. 'Saying that owning your home is a terrible investment is a blanket statement that dismisses what has been the primary source of wealth-building for nearly 70% of Americans,' said Jose Alvarez, founding advisor at Harvest Horizon Wealth Strategies. 'For someone who built a career in real estate, that stance seems like nothing more like marketing for traffic on his platforms.' However, he did agree that you shouldn't consider your home an investment. Instead, he said it should be viewed as an item of consumption that serves as a place to live. 'You buy it to create stability — not to liquidate it later for income,' he said. 'That's not a home's purpose.' Unlike traditional investments, he acknowledged that your home probably won't produce income — unless you're a real estate developer. 'When you factor in maintenance costs that don't improve your basis — new roof, windows, painting — plus insurance, property taxes and utility costs, the real rate of return — return adjusted for CPI — on a primary residence tends to hover around 2% to 3% over a 20-year period,' he said. 'That's barely outpacing inflation and it's tied up in an illiquid asset.' Despite this, he said homeownership can definitely be part of a solid long-term financial plan. He also noted that calling it a terrible investment ignores the overall value its designed to offer. More From GOBankingRates Mark Cuban Warns of 'Red Rural Recession' -- 4 States That Could Get Hit Hard 5 Types of Cars Retirees Should Stay Away From Buying Mark Cuban Tells Americans To Stock Up on Consumables as Trump's Tariffs Hit -- Here's What To Buy This article originally appeared on Grant Cardone's Most Hated Advice: Does It Make Sense For You?
